Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6942905 | 1.00 | TDP1 (0.53) | TDP1L3MBTL1MEN1KMT2ASIGMAR1 | |
| SCHEMBL10477865 | 1.00 | TDP1 (0.53) | TDP1L3MBTL1MEN1KMT2ASIGMAR1 | |
| SCHEMBL9257077 | 1.00 | TDP1 (0.53) | TDP1L3MBTL1MEN1KMT2ASIGMAR1 | |
| SCHEMBL9258098 | 1.00 | TDP1 (0.53) | TDP1L3MBTL1MEN1KMT2ASIGMAR1 | |
| SCHEMBL7621746 | 1.00 | TDP1 (0.53) | TDP1L3MBTL1MEN1KMT2ASIGMAR1 | |
| SCHEMBL9574235 | 1.00 | TDP1 (0.53) | TDP1L3MBTL1MEN1KMT2ASIGMAR1 | |
| SCHEMBL9258414 | 0.98 | TDP1 (0.52) | TDP1L3MBTL1MEN1KMT2ASIGMAR1 | |
| SCHEMBL9262777 | 0.96 | IDO1 (0.52) | TDP1L3MBTL1MEN1KMT2ASIGMAR1 | |
| SCHEMBL9257411 | 0.96 | IDO1 (0.52) | TDP1L3MBTL1MEN1KMT2ASIGMAR1 | |
| SCHEMBL10465461 | 0.96 | TDP1 (0.53) | TDP1L3MBTL1MEN1KMT2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7112701-B2 | Process for the manufacture of 4-(6-bromohexyloxy)-butylbenzene | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-09-26 | — | — | US | claimed |
| EP-1483226-B1 | IMPROVED METHOD FOR THE PRODUCTION OF 4-(6-BROMOHEXYLOXY) BUTYLBENZENE | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-09-07 | — | — | EP | claimed |
| US-20050113608-A1 | Process for the manufacture of 4-(6-bromohexyloxy)-butylbenzene | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-05-26 | — | — | US | claimed |
| US-6835857-B2 | Process for the manufacture of 4-(6-bromohexyloxy)-butylbenzene | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-12-28 | — | — | US | claimed |
| EP-1483226-A1 | IMPROVED METHOD FOR THE PRODUCTION OF 4-(6-BROMOHEXYLOXY) BUTYLBENZENE | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-12-08 | — | — | EP | claimed |
| WO-2003074458-A1 | IMPROVED METHOD FOR THE PRODUCTION OF 4-(6-BROMOHEXYLOXY) BUTYLBENZENE | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2003-09-12 | — | — | WO | claimed |
| US-20030171620-A1 | Process for the manufacture of 4-(6-bromohexyloxy)-butylbenzene | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-09-11 | — | — | US | claimed |
| CN-119970731-A | Inhalation dry powder preparation containing salmeterol and tiotropium salt composition and preparation method thereof | 南昌弘益科技有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-119923380-A | N-substituted phenylalkylamines and their use as therapeutic agents | 亚历山大舒尔金研究所有限公司 | 2025-05-02 | — | — | CN | disclosed |
| EP-4543833-A1 | N-SUBSTITUTED PHENYLALKYLAMINES AND THEIR USE AS THERAPEUTIC AGENTS | Alexander Shulgin Research Institute, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| WO-2024006226-A1 | N-SUBSTITUTED PHENYLALKYLAMINES AND THEIR USE AS THERAPEUTIC AGENTS | ALEXANDER SHULGIN RESEARCH INSTITUTE, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| EP-3201171-B1 | METHOD OF PREPARING INTERMEDIATE OF SALMETEROL | AMPHASTAR NANJING PHARMACEUTICALS INC (CN) | 2020-04-15 | — | — | EP | disclosed |
| WO-2017168431-A1 | PROCESS FOR THE PREPARATION OF SALMETEROL XINAFOATE | DAVULURI RAMAMOHAN RAO (IN) | 2017-10-05 | — | — | WO | disclosed |
| US-5225445-A | Respiratory system disorders | GLAXO GROUP LTD. | 1993-07-06 | — | — | US | disclosed |
| US-5126375-A | Asthma, chronic bronchitis | GLAXO GROUP LTD. (GB) | 1992-06-30 | — | — | US | disclosed |
| US-5091422-A | Treating inflammatory or allergic skin disease, lowering gastric acidity | GLAXO GROUP LIMITED (GB) | 1992-02-25 | — | — | US | disclosed |
| US-4992474-A | Adrenergic stimulants | GLAXO GROUP LTD. (GB) | 1991-02-12 | — | — | US | disclosed |
| US-4908386-A | Pharmaceuticals | GLAXO GROUP LIMITED (GB) | 1990-03-13 | — | — | US | disclosed |
| US-4853381-A | Ethanolamine compounds | GLAXO GROUP LIMITED (GB) | 1989-08-01 | — | — | US | disclosed |
| EP-0220054-A2 | Ethanolamine derivatives | GLAXO GROUP LIMITED (GB) | 1987-04-29 | — | — | EP | disclosed |